Reason for request
Reassessment
Clinical Benefit
| Insufficient |
The Committee deems that the clinical benefit of BLENREP (belantamab mafodotin) 100 mg, powder for solution for dilution for infusion, is insufficient in the MA indication to justify public funding. |
Clinical Added Value
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
QhL8CX6HCCyEP8WF
